These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6850578)

  • 1. Host cathepsin D response to tumor in the normal and pepstatin-treated mouse.
    Greenbaum LM; Sutherland JH
    Cancer Res; 1983 Jun; 43(6):2584-7. PubMed ID: 6850578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscle aspartyl protease (cathepsin D) activity: detection using a chromophoric substrate and relation to wasting in DBA/2 mice implanted with leukemic L1210 tumor cells.
    Bolger GT; Jaramillo J
    Can J Physiol Pharmacol; 1996 Oct; 74(10):1141-8. PubMed ID: 9022834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional brain distribution of cathepsin D activity: its inhibition in vivo following central infusion of pepstatin in the rat.
    Buccafusco JJ; Goldstein BD; Greenbaum LM
    Res Commun Chem Pathol Pharmacol; 1982 Apr; 36(1):157-60. PubMed ID: 7079582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endosomal-lysosomal proteolysis mediates death signalling by TNFalpha, not by etoposide, in L929 fibrosarcoma cells: evidence for an active role of cathepsin D.
    Démoz M; Castino R; Cesaro P; Baccino FM; Bonelli G; Isidoro C
    Biol Chem; 2002; 383(7-8):1237-48. PubMed ID: 12437111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The lysosomal cathepsins B, L and D in development of murine experimental leukemias].
    Khalikova TA; Korolenko TA; Il'nitskaia SI
    Biomed Khim; 2009; 55(5):621-34. PubMed ID: 20017393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pepstatin, an inhibitor of leukokinin formation and ascitic fluid accumulation.
    Greenbaum LM; Grebow P; Johnston M; Prakash A; Semente G
    Cancer Res; 1975 Mar; 35(3):706-10. PubMed ID: 46779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pepstatin, an inhibitor of acid kininogenases and ascites retardant in neoplastic disease.
    Greenbaum LM
    Fed Proc; 1979 Dec; 38(13):2788-91. PubMed ID: 92421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cysteine proteinase activity by Z-Phe-Phe-diazomethane and of aspartic proteinase activity by pepstatin in different organs from some animals and isolated cells from rat liver.
    Riemann S; Kirschke H; Wiederanders B; Brouwer A; Shaw E; Bohley P
    Acta Biol Med Ger; 1982; 41(1):83-8. PubMed ID: 7051705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological activity of aspartic proteinase inhibitors related to pepstatin.
    Gunn JM; Owens RA; Liu WS; Glover GI
    Acta Biol Med Ger; 1981; 40(10-11):1547-53. PubMed ID: 6805191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No role for pepstatin-A-sensitive acidic proteinases in reovirus infections of L or MDCK cells.
    Kothandaraman S; Hebert MC; Raines RT; Nibert ML
    Virology; 1998 Nov; 251(2):264-72. PubMed ID: 9837790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Kininogenase activity of cathepsins D].
    Ogloblina OG; Ruanet VV; Kazakova OV; Paskhina TS; Orekhovich VN
    Biokhimiia; 1980 Dec; 45(12):2217-24. PubMed ID: 6941816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimetastatic activity of adriamycin in combinations with proteinase inhibitors in mice.
    Leto G; Tumminello FM; Gebbia N; Woynarowska B; Bernacki RJ
    Anticancer Res; 1990; 10(1):265-9. PubMed ID: 2334138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related changes in activities and localizations of cathepsins D, E, B, and L in the rat brain tissues.
    Nakanishi H; Tominaga K; Amano T; Hirotsu I; Inoue T; Yamamoto K
    Exp Neurol; 1994 Mar; 126(1):119-28. PubMed ID: 8157122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of activity of cathepsins B, L, and D in murine lymphosarcoma model at a combined treatment with cyclophosphamide and yeast polysaccharide.
    Khalikova TA; Zhanaeva SY; Korolenko TA; Kaledin VI; Kogan G
    Cancer Lett; 2005 Jun; 223(1):77-83. PubMed ID: 15890239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of E-64 (cysteine-proteinase inhibitor) and pepstatin (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovarian tumors.
    Leto G; Pizzolanti G; Tumminello FM; Gebbia N
    In Vivo; 1994; 8(2):231-6. PubMed ID: 7919127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of cathepsin D in the invasiveness of human breast cancer cells.
    Johnson MD; Torri JA; Lippman ME; Dickson RB
    Cancer Res; 1993 Feb; 53(4):873-7. PubMed ID: 8428368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Isolation of cathepsin D from the aorta using pepstatin sepharose].
    Pichugin AL; Kazakova OV
    Vopr Med Khim; 1979; 25(6):741-3. PubMed ID: 516535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pepstatin on reducing hypoxia-induced injury in the isolated guniea pig heart.
    Logan ME; Greenbaum LM
    Res Commun Chem Pathol Pharmacol; 1982 Aug; 37(2):243-58. PubMed ID: 7134630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The catalytically inactive precursor of cathepsin D induces apoptosis in human fibroblasts and HeLa cells.
    Schestkowa O; Geisel D; Jacob R; Hasilik A
    J Cell Biochem; 2007 Aug; 101(6):1558-66. PubMed ID: 17340625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of in vivo inhibition of tissue cathepsin D by pepstatin A.
    Leto G; Tumminello FM; Gebbia N; Rausa L
    Int J Biochem; 1988; 20(9):917-20. PubMed ID: 3197907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.